McNeilHPSimpsonRJChestermanCN. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120–4.
2.
GalliMComfuriusPMaassenC. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990; 335: 1544–7.
3.
MatsuuraEIgarashiYFujimotoM. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177–8.
4.
HuntJEMcNeilHPMorganGJ. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus1992; 1: 83–90.
5.
McNeilHPChestermanCNKrilisSA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol1991; 49: 193–279.
6.
HarrisENGharaviAEBoeyML. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet1983; 2: 1211–14.
7.
LovePESantoroSA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med1990; 112: 682–98.
8.
LongAAGinsbergJSBrill-EdwardsP. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study. Thromb Haemos1991; 66: 520–4.
9.
ArvieuxJRousselBJacobMC. Measurement of antiphospholipid antibodies by ELISA using Beta 2 glycoprotein I as an antigen. J Immunol Meth1991; 143: 223–9.
10.
ViardJPAmouraZBachJF. Association of anti-beta-2 glycoprotein I antibodies with lupus-type circulating anticoagulants and thrombosis in systemic lupus erythematosus. Am J Med1992; 93: 181–6.
11.
MatsuuraEIgarashiYFujimotoM. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885–91.
MatsuuraEIgarashiYYasudaT. Anticardiolipin antibodies recognize β2 glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med1994; 179: 457–62.
15.
HarrisENPierangeliSBarquineroJ. Anticardiolipin antibodies and binding of anionic phospholipids and serum protein. Lancet1990; 336: 505–6.
16.
HarrisENPierangeliS. What is the ‘true’ antigen for antiphospholipid antibodies?Lancet1990; 336: 1505.
17.
LozierJTakahashiNPutnamFW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA1984; 81: 3640–4.
18.
KrollJLarsenJKLoftH. DNA-binding protein in Yoshida ascites tumour fluid. Biochim Biophys Acta1976; 434: 490–501.
19.
SchousboeI. Characterization of the interaction between beta 2-glycoprotein I and mitochondria, platelets, liposomes and bile acids. Int J Biochem1983; 15: 1393–401.
20.
ReidKBMDayAJ. Structure-function relationships of the complement components. Immunology Today1989; 10: 177–80.
21.
SteinkassererAEstallerCWeissEH. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I. Biochem J1991; 277: 387–91.
22.
HuntJESimpsonRJKrilisSA. Identification of a region of Beta-2-glycoprotein I critical for lipid-binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci USA1993; 90: 2141–5.
23.
HuntJEKrilisSA. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol1994; 152: 653–9.
24.
ThorellJIJohanssonBG. Enzymatic iodination of polypeptides with 125I to high specific activity. Biochem Biophys Acta1971; 251: 363–9.
25.
SteinkassererABarlowPNWillisAC. Activity, disulphide mapping and structural modelling of the fifth domain of human β2-glycoprotein I. FEBS1992; 313: 193–7.
26.
NormanDGBarlowPNBaronM. Three-dimensional structure of a complement control protein module in solution. J Mol Biol1991; 219: 717–25.
27.
KhamashtaMAIchikawaKHughesGRV. β2-glycoprotein I dependency and reactivity to platelets of monoclonal anticardiolipin antibodies raised from patients with the antiphospholipid syndrome. Arthritis Rheum1993; 36 (Suppl): 74 (abstract 215).
